6814 Stock Overview
Lukas Biomedical Inc. engages in the development of immune cell medical technology for regenerative medicine and auxiliary treatment of cancer in Taiwan.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Lukas Biomedical Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$29.90 |
| 52 Week High | NT$39.75 |
| 52 Week Low | NT$22.50 |
| Beta | 0.081 |
| 1 Month Change | 0% |
| 3 Month Change | 7.94% |
| 1 Year Change | -21.11% |
| 3 Year Change | -47.17% |
| 5 Year Change | n/a |
| Change since IPO | -44.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6814 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | -0.3% | -1.1% | -0.6% |
| 1Y | -21.1% | -21.5% | 29.2% |
Return vs Industry: 6814 matched the TW Biotechs industry which returned -21.5% over the past year.
Return vs Market: 6814 underperformed the TW Market which returned 29.2% over the past year.
Price Volatility
| 6814 volatility | |
|---|---|
| 6814 Average Weekly Movement | 3.8% |
| Biotechs Industry Average Movement | 4.8% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in TW Market | 8.7% |
| 10% least volatile stocks in TW Market | 2.2% |
Stable Share Price: 6814 has not had significant price volatility in the past 3 months.
Volatility Over Time: 6814's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 88 | n/a | lukas-bio.com.tw |
Lukas Biomedical Inc. engages in the development of immune cell medical technology for regenerative medicine and auxiliary treatment of cancer in Taiwan. It operates through four divisions: E-commerce, Medical Management Business, Cell Product, and Pharmaceutical Market. The company also wholesales and retails cosmetics; and rents housing equipment.
Lukas Biomedical Inc. Fundamentals Summary
| 6814 fundamental statistics | |
|---|---|
| Market cap | NT$1.10b |
| Earnings (TTM) | -NT$47.35m |
| Revenue (TTM) | NT$231.83m |
4.8x
P/S Ratio-23.3x
P/E RatioIs 6814 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6814 income statement (TTM) | |
|---|---|
| Revenue | NT$231.83m |
| Cost of Revenue | NT$97.94m |
| Gross Profit | NT$133.89m |
| Other Expenses | NT$181.24m |
| Earnings | -NT$47.35m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.28 |
| Gross Margin | 57.75% |
| Net Profit Margin | -20.43% |
| Debt/Equity Ratio | 29.5% |
How did 6814 perform over the long term?
See historical performance and comparison